A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Deflazacort Oral

Deflazacort Oral reduces inflammation and suppresses immune responses, used across many conditions.

First FDA approval2024-05-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
23 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema6 entries indexed · 4 visible
What is Deflazacort Oral used for?

Deflazacort Oral reduces inflammation and suppresses immune responses, used across many conditions.

Is there a generic for Deflazacort Oral?

No. Deflazacort Oral is brand-only with no generic equivalents currently in market.

How much does my plan pay for Deflazacort Oral?

NADAC pricing data not currently available for this drug.

Is Deflazacort Oral on the FDA shortage list?

No. Deflazacort Oral is not currently on the FDA Drug Shortage Database.

2 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.